TOPICAL DELIVERY OF NANOEMULSION FOR ANTIPSORIATIC DRUGS
Psoriasis is an autoimmune disorder of the skin characterized by relapsing episodes of inflammatory lesions and hyperkeratotic plaques with worldwide occurrence of around 2–5%. Psoriasis is a disease known to be caused by multitude of both genetic and environmental factors such as trauma, drugs, infection, alcohol, smoking and stress but its accurate origin is still not known. Further, available treatment options are associated with both inappropriate cosmetic appearance and related toxicities leading to poor patient compliance in long term use. Nanotechnology based drug delivery system has immense potential to enhance the bioavailability and effectiveness of drugs in their dosage forms, especially lipophilic drugs. Lipid based carrier system can overcome the lipid imbalance and normal moisturizing factors. Nanoemulsions, as one of a new carrier apparently have the prospective to conquer numerous problems related with topical antipsoriatic therapy. This delivery system could perhaps offer a good alternative in topical psoriasis treatment. Not only on how nanoemulsions prepared, but it depends on the active ingredients used and the selection of oil could as well enhance the efficiency of topical treatment towards psoriasis. A good combination of both active and suitable oils would result a better treatment and better effect.
Keywords: Topical nanoemulsion, Antipsoriatic therapy, Critical quality attributes.
2. Chaturvedi SP, Kumar V, a review on disease management and drug delivery aspects in psoriasis, Current Trends In Technology And Science, 2012; 1(3):122-125.
3. El-Darouti M, Hay RB, Psoriasis: highlights on pathogenesis, adjuvant therapy and treatment of resistant and problematic cases (part I), J. Egypt. Women. Dermatol. Soc. 2010; 64–67.
4. Kim MK, Chung SJ, Lee MH, Shim CK, Delivery of hydrocortisone from liposomal suspensions to the hairless mouse skin following topical application under non-occlusive and occlusive conditions, J. Microencapsul. 1998; 15:21–29.
5. Lei W, Yu C, Lin H, Zhou X, Development of tacrolimus-loaded transfersomes for deeper skin penetration enhancement and therapeutic effect improvement in vivo, Asian J. Pharm. Sci. 2013; 8:336–345.
6. Cavalli R, Peira E, Caputo O, Gasco MR, Solid lipid nanoparticles as carriers of hydrocortisone and progesterone complexes with beta-cyclodextrins, Int. J. Pharm. 1999; 182:59–69.
7. Vafaei SY, Dinarvand R, Esmaeili M, Mahjub R, Toliyat T, Controlled-release drug delivery system based on fluocinolone acetonide-cyclodextrin inclusion complex incorporated in multivesicular liposomes, Pharm. Dev. Technol. 2014; 1–7.
8. Behera J, Keservani RK, Yadav A, Tripathi M, Chadoker A, Methoxsalen loaded chitosan coated microemulsion for effective treatment of psoriasis, Int. J. Drug Deliv. 2011; 2.
9. Ishihara T, Izumo N, Higaki M, Shimada E, Hagi T, Mine L, Role of zinc in formulation of PLGA/PLA nanoparticles encapsulating betamethasone phosphate and its release profile, J. Control. Release Off. J. Control. Release Soc. 2005; 105:68–76.
10. Özcan I, Azizoğlu E, Senyiğit T, Özyazici M, Özer Ö, Comparison of PLGA and lecithin/chitosan nanoparticles for dermal targeting of betamethasone valerate, J. Drug Target. 2013; 21:542–550.
11. Jain S,. Mittal A, Jain AK, Enhanced topical delivery of cyclosporine A using PLGA nanoparticles as carrier, Curr. Nanosci. 2011; 7:524–530.
12. Badıllı U, Sen T, Tarımcı N, Microparticulate based topical delivery system of clobetasol propionate, AAPS PharmSciTech. 2011; 12:949–957.
13. Gómez-Gaete C, Tsapis N, Besnard M, Bochot A, Fattal E, Encapsulation of dexamethasone into biodegradable polymeric nanoparticles, Int. J. Pharm. 2007; 331:153–159.
14. Friedrich RB, Fontana MC, Beck RCR, Pohlmann AR, Guterres SS, Development and physicochemical characterization of dexamethasone-loaded polymeric nanocapsule suspensions, Quím. Nova. 2008; 31:1131–1136.
15. Rosado C, Silva C, Reis CP, Hydrocortisone-loaded poly(ε-caprolactone) nanoparticles for atopic dermatitis treatment, Pharm. Dev. Technol. 2013; 18:710–718.
16. Lapteva M, Santer V, Mondon K, Patmanidis I, Chiriano G, Scapozza L, Targeted cutaneous delivery of ciclosporin A using micellar nanocarriers and the possible role of inter- cluster regions as molecular transport pathways, J. Controlled Release. 2014; 196:9–18.
17. Singka GSL, Samah NA, Zulfakar MH, Yurdasiper A, Heard CM, Enhanced topical delivery and anti-inflammatory activity of methotrexate from an activated nanogel, Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft Für Pharm. Verfahrenstechnik EV. 2010; 76:275–281.
18. Lapteva M, Mondon K, Möller M, Gurny R, Kalia YN, Polymeric micelle nanocarriers for the cutaneous delivery of tacrolimus: a targeted approach for the treatment of psoriasis, Mol. Pharm. 2014; 11:2989–3001.
19. Priprem A, Limsitthichaikoon S, Thappasarapong S, Anti-Inflammatory Activity of Topical Anthocyanins by Complexation and Niosomal Encapsulation, (n.d.). http://www.waset.org/publications/10000421 (accessed May 11, 2015).
20. Agarwal R, Katare OP, Vyas SP, Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol, Int. J. Pharm. 2001; 228:43–52.
21. Abdelbary AA, AbouGhaly MHH, Design and optimization of topical methotrexate loaded niosomes for enhanced management of psoriasis: Application of Box-Behnken design, in-vitro evaluation and in-vivo skin deposition study, Int. J. Pharm. 2015; 485:235–243.
22. Senyiğit T, Sonvico F, Barbieri S, Ozer O, Santi P, Colombo P, Lecithin/chitosan nanoparticles of clobetasol-17-propionate capable of accumulation in pig skin, J. Control. Release Off. J. Control. Release Soc. 2010; 142:368–373.
23. Körbel JN, Sebök B, Kerényi M, Mahrle G, Enhancement of the antiparakeratotic potency of calcitriol and tacalcitol in liposomal preparations in the mouse tail test, Skin Pharmacol. Appl. Skin Physiol. 2001; 14:291–295.
24. Rao G, Murthy RSR, Evaluation Of Liposomal Clobetasol Propionate Topical Formulation For Intra- Dermal Delivery, Indian J. Pharm. Sci. 2000; 62:459.
25. Agarwal R, Saraswat A, Kaur I, Katare OP, Kumar B, A novel liposomal formulation of dithranol for psoriasis: preliminary results, J. Dermatol. 2002; 29:529–532.
26. Raza K, Singh B, Lohan S, Sharma G, Negi P, Yachha Y, Nano-lipoidal carriers of tretinoin with enhanced percutaneous absorption, photostability, biocompatibility and anti- psoriatic activity, Int. J. Pharm. 2013; 456:65–72.
27. Yu HY, Liao HM, Triamcinolone permeation from different liposome formulations through rat skin in vitro, Int. J. Pharm. 1996; 127:1–7.
28. Knudsen NØ, Rønholt S, Salte RD, Jorgensen L, Thormann T, Basse LH, Calcipotriol delivery into the skin with PEGylated liposomes, Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft Für Pharm. Verfahrenstechnik EV. 2012 81:532–539.
29. Cevc G, Blume G, Hydrocortisone and dexamethasone in very deformable drug carriers have increased biological potency, prolonged effect, and reduced therapeutic dosage, Biochim. Biophys. Acta BBA-Biomembr. 2004; 1663:61–73.
30. Fesq H, Lehmann J, Kontny A, Erdmann I, Theiling K, Rother M, Improved risk-benefit ratio for topical triamcinolone acetonide in Transfersome in comparison with equipotent cream and ointment: a randomized controlled trial, Br. J. Dermatol. 2003; 149:611–619.
31. Guo J, Ping Q, Sun G, Jiao C, Lecithin vesicular carriers for transdermal delivery of cyclosporin A, Int. J. Pharm. 2000; 194: 201–207.
32. Srisuk P, Thongnopnua P, Raktanonchai U, Kanokpanont S, Physico-chemical characteristics of methotrexate-entrapped oleic acid-containing deformable liposomes for in vitro transepidermal delivery targeting psoriasis treatment, Int. J. Pharm. 2012; 427:426–434.
33. Trotta M, Peira E, Carlotti ME, Gallarate M, Deformable liposomes for dermal administration of methotrexate, Int. J. Pharm. 2004; 270:119–125.
34. Verma DD, Fahr A, Synergistic penetration enhancement effect of ethanol and phospholipids on the topical delivery of cyclosporin A, J. Control. Release Off. J. Control. Release Soc. 2004; 97:55–66.
35. Dubey V, Mishra D, Dutta T, Nahar M, Saraf DK, Jain NK, Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes, J. Control. Release Off. J. Control. Release Soc. 2007; 123:148–154.
36. Zhang YT, Shen LN, Zhao JH, Feng NP, Evaluation of psoralen ethosomes for topical delivery in rats by using in vivo microdialysis, Int. J. Nanomedicine. 2014; 9:669–678.
37. Li G, Fan Y, Fan C, Li X, Wang X, Li M, Tacrolimus-loaded ethosomes: physicochemical characterization and in vivo evaluation, Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft Für Pharm. Verfahrenstechnik EV. 2012; 82:49–57.
38. Zhang J, Smith E, Percutaneous permeation of betamethasone 17-valerate incorporated in lipid nanoparticles, J. Pharm. Sci. 2011; 100:896–903.
39. Kim ST, Jang DJ, Kim JH, Park JY, Lim JS, Lee SY, Topical administration of cyclosporin A in a solid lipid nanoparticle formulation, Pharm. 2009; 64:510–514.
40. Kalariya M, Padhi BK, Chougule M, Misra A, Clobetasol propionate solid lipid nanoparticles cream for effective treatment of eczema: formulation and clinical implications, Indian J. Exp. Biol. 2005; 43:233–240.
41. Gambhire MS, Bhalekar MR, Gambhire VM, Statistical optimization of dithranol-loaded solid lipid nanoparticles using factorial design, Braz. J. Pharm. Sci. 2011; 47:503–511.
42. Luigi EP, Lipid Nanosystems in Topical PUVA Therapy, J. Dispers. Sci. Technol. 2011; 33:565–569.
43. Madan JR, Khude PA, Dua K, Development and evaluation of solid lipid nanoparticles of mometasone furoate for topical delivery, Int. J. Pharm. Investig. 2014; 4:60–64.
44. Schlupp P, Blaschke T, Kramer KD, Höltje HD, Mehnert W, Schäfer-Korting M, Drug release and skin penetration from solid lipid nanoparticles and a base cream: a systematic approach from a comparison of three glucocorticoids, Skin Pharmacol. Physiol. 2011; 24:199– 209.
45. Fang JY, Fang CL, Liu CH, Su YH, Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC), Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft Für Pharm. Verfahrenstechnik EV. 2008; 70:633–640.
46. Pradhan M., Singh D,. Singh MR, Influence of selected variables on fabrication of Triamcinolone acetonide loaded solid lipid nanoparticles for topical treatment of dermal disorders, Artif. Cells Nanomedicine Biotechnol. 2014; 1–9.
47. Sonawane R, Harde H, Katariya M, Agrawal S, Jain S, Solid lipid nanoparticles-loaded topical gel containing combination drugs: an approach to offset psoriasis, Expert Opin. Drug Deliv. 11 (2014) 1833–1847.
48. Bikkad ML, Nathani AH, Mandlik SK, Shrotriya SN, Ranpise NS, Halobetasol propionate- loaded solid lipid nanoparticles (SLN) for skin targeting by topical delivery, J. Liposome Res. 2014; 24:113–123.
49. Ruihua W, FK506-loaded solid lipid nanoparticles: Preparation, characterization and in vitro transdermal drug delivery, Afr. J. Pharm. Pharmacol. 2012; 6.
50. Lin YK, Huang ZR,. Zhuo RZ, Fang JY, Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical delivery, Int. J. Nanomedicine. 2010; 5:117–128.
51. Silva LAD, Taveira SF, Lima EM, Marreto RN, In vitro skin penetration of clobetasol from lipid nanoparticles: drug extraction and quantitation in different skin layers, Braz. J. Pharm. Sci. 2012; 48:811–817.
52. Pradhan M, Singh D, Singh MR, Development characterization and skin permeating potential of lipid based novel delivery system for topical treatment of psoriasis, Chem. Phys. Lipids. 2015; 186:9–16.
53. Pinto MF, Moura CC, Nunes C,. Segundo MA, Lima SAC, Reis S, A new topical formulation for psoriasis: development of methotrexate-loaded nanostructured lipid carriers, Int. J. Pharm. 2014; 477:519–526.
54. Nam SH, Ji XY, Park JS, Investigation of Tacrolimus Loaded Nanostructured Lipid Carriers for Topical Drug Delivery, Bull. Korean Chem. Soc. 2011; 32:956–960.
55. Baboota S, Alam MS, Sharma S, Sahni JK, Kumar A, Ali J, Nanocarrier-based hydrogel of betamethasone dipropionate and salicylic acid for treatment of psoriasis, Int. J. Pharm. Investig. 2011; 1:139–147.
56. Raza K, Negi P, Takyar S, Shukla A, Amarji B, Katare OP, Novel dithranol phospholipid microemulsion for topical application: development, characterization and percutaneous absorption studies, J. Microencapsul. 2011; 28:190–199.
57. Baroli B, López-Quintela MA, Delgado-Charro MB, Fadda AM, Blanco-Méndez J, Microemulsions for topical delivery of 8-methoxsalen, J. Control. Release Off. J. Control. Release Soc. 2000; 69:209–218.
58. Sah AK, Jain SK, Pandey RS, Microemulsion based hydrogel formulation of methoxsalen for the effective treatment of psoriasis, Asian J. Pharm. Clin. Res. 2011; 4:140–145.
59. Shinde G, Rajesh KS, Prajapati N, Murthy RSR, Formulation, development and characterization of nanostructured lipid carrier (NLC) loaded gel for psoriasis, Der Pharmacia Lettre, 2013; 5:13- 25.
60. Wohlrab J, Goebel A, Scherer D, Bingham D, Reinhard HH, A Topical Tacrolimus, Microemulsion for Plaque-Type Psoriasis Therapy, Drug Development & Delivery 2012; 12.
61. Vicentini FTMC, Depieri LV,. Polizello ACM, Ciampo JOD, Spadaro ACC, Fantini MCA, Bentley MVLB, Liquid crystalline phase nanodispersions enable skin delivery of siRNA, Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft Für Pharm. Verfahrenstechnik EV. 2013; 83:16–24.
62. Marepally S, Boakye CHA, Patel AR, Godugu C, Doddapaneni R, Desai PR, Singh M, Topical administration of dual siRNAs using fusogenic lipid nanoparticles for treating psoriatic- like plaques, Nanomed. 2014; 9: 2157–2174.
63. Lopes LB, Lopes JLC, Oliveira DCR, Thomazini JA, Garcia MTJ,. Fantini MCA, Collett JH, Bentley MVLB, Liquid crystalline phases of monoolein and water for topical delivery of cyclosporin A: characterization and study of in vitro and in vivo delivery, Eur. J. Pharm. Biopharm. Off. J. Arbeitsgemeinschaft Für Pharm. Verfahrenstechnik EV. 2006; 63:146–155.
64. Thapa RK, Yoo BK, Evaluation of the effect of tacrolimus-loaded liquid crystalline nanoparticles on psoriasis-like skin inflammation, J. Dermatol. Treat. 2014; 25:22–25.
65. Petrilli R, Eloy JO, Praça FSG, Ciampo JOD, Fantini MAC, Fonseca MJV, Bentley MVLB, Liquid Crystalline Nanodispersions Functionalized with Cell-Penetrating Peptides for Topical Delivery of Short-Interfering RNAs: A Proposal for Silencing a Pro-Inflammatory Cytokine in Cutaneous Diseases, J. Biomed. Nanotechnol. 2016; 12:1063–1075.
66. Nickoloff BJ, Nestle FO, Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities, J. Clin. Invest. 2004; 113:1664–1675.
67. Jaiswal M, Dudhe R, Sharma PK, Nanoemulsion: an advanced mode of drug delivery system, Biotech, 2015; 5:123–127
68. Christofori M, Nastiti RR, Ponto T, Abd E, Grice JE, Heather A, Benson E, Roberts MS, Topical nano and microemulsions for skin delivery, Pharmaceutics 2017; 9:37, 1-25.
69. Salim N, Ahmad N, Musa SH, Hashim R,. Tadrosc T F, Basriad M, Nanoemulsion as a topical delivery system of antipsoriatic drugs , Royal society of chemistry adv. 2016; 6:6234–6250
70. Setya S, Talegaonkar S, Razdan BK, Nanoemulsions:formulation methods and stability aspects, world journal of pharmacy and pharmaceutical sciences 2014; (3)2: 2214-2228.
71. Prabu SL, Sharvana SP, Aravindan S, Bhuvaneswari A, Manikandan V, Nanoemulgel for transdermal delivery of cyclobenzaprine hydrochloride: design, characterization and in-vitro studies, PLoS ONE 2017; 1(5):1-6.
72. Çinar K, A review on nanoemulsions: preparation methods and stability, Trakya University Journal of Engineering Sciences, 2017; 18(1):73-83,
73. Somagoni J, Boakye CHA, Godugu C,. Patel AR, Mendonca HAF, Zucolotto V, Sachdeva M, Nanomiemgel - a novel drug delivery system for topical application - in vitro and in vivo evaluation. PLoS ONE, 2014; 9(12):e115952.
74. Ali S, Alam S, Imam F, Siddiqui MR, Topical nanoemulsion of turmeric oil for psoriasis: characterization, ex vivo and in vivo assessment. International Journal of Drug Delivery 2012; 4:184-197
75. Kaur A, Katiyar SS, Kushwah V, Jain S, Nanoemulsion loaded gel for topical co-delivery of clobitasol propionate and calcipotriol in psoriasis, Nanomedicine, 2017; 13(4):1473-1482
76. Alam S, Ali S, Alam N, Alam I, Anwer T, Imam F, Ali D, Siddiqui MR, Shamim M, Design and Characterization of Nanostructure Topical Gel of Betamethasone Dipropionate for Psoriasis . J App Pharm Sci. 2012; 2(10):148-158.
77. Baboota S, Alam S, Sharma S, . Sahni JK, Kumar A, Ali J, Nanocarrier-based hydrogel of betamethasone dipropionate and salicylic acid for treatment of psoriasis, Int J Pharm Investig. 2011; 1(3):139–147.
78. Alam S, Ali S, Alam N, Siddiqui MR, Shamim M, Safhi MM, In vivo study of clobetasol propionate loaded nanoemulsion for topical application in psoriasis and atopic dermatitis, Drug invention today 2013 ; 5:8 -1 2.
79. Ali S, Alam S, Alam N, Qadry SAS, Alam I, Shamim M, Ali D, Formulation, characterization and in-vivo assessment of topical nanoemulsion of betamethasone valerate for psoriasis and dermatose. Int J Pharm 2013; 3(1):186-199.
80. Musa SH, Basri M, Masoumi HRF, Shamsudin N, Salim N, Enhancement of physicochemical properties of nanocolloidal carrier loaded with cyclosporine for topical treatment of psoriasis: in vitro diffusion and in vivo hydrating action, International Journal of Nanomedicine. 2017; 12:2427–2441.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).